Annual Conference

"From Concept to the Clinic"

The 13th Annual Personalized Medicine Conference will define the landscape, outlook and next steps for personalized medicine in science, business and policy.

November 14 - 16, 2017
Joseph B. Martin Conference Center
Harvard Medical School

Speakers (K - Z)

Speakers for the 13th Annual Personalized Medicine Conference provide head shots and biographical descriptions on a rolling basis.

Sean Khozin, M.D., M.P.H.
Associate Director (Acting)
Oncology Center of Excellence

Dr. Khozin is a thoracic oncologist, acting associate director at FDA’s Oncology Center of Excellence, and the founding director of Information Exchange and Data Transformation (INFORMED), a data science and technology incubator focused on supporting innovations that enhance FDA’s mission of promotion and protection of the public health. Drawing from the expertise of a diverse group of oncologists, data scientists, statisticians and entrepreneurs-in-residence, INFORMED is expanding organizational and technical infrastructure for big data analytics and examining modern approaches in evidence generation to support regulatory decisions. The research portfolio of INFORMED includes investigations into real world data for clinical evidence generation, biosensors and the internet of things to quantify intrinsic and extrinsic factors influencing the patient’s experience, machine learning and artificial intelligence, and blockchain to enable secure exchange of health data at scale.

Previously, Dr. Khozin was in private practice in New York City, an attending physician at St. Vincent’s Hospital in Manhattan, and an entrepreneur specializing in building health information technology systems with virtual patient management (including video, structured email, short message service and remote biometric monitoring) and point-of-care data visualization and analytics capabilities.

Eric G. Klein, Pharm.D.
Senior Director, Oncology, Global Patient Outcomes,
Real World Evidence
Eli Lilly and Company

Dr. Klein is currently Senior Director, Oncology in the Global Patient Outcomes and Real World Evidence Department at Eli Lilly and Company. In this role, Dr. Klein leads the Outcomes Research team supporting the Oncology Business Unit and is responsible for the health economic, outcomes research, and real-world evidence capabilities supporting Lilly’s early and late phase drug development efforts in oncology.

Dr. Klein has spent the last 20 years is leadership roles responsible for various aspects of the Outcomes Research and Real World Evidence organization at Lilly. Dr. Klein joined the Outcomes Research organization of Lilly USA in January of 1998 where he spent six years focused on building the organizations capabilities. In September 2004, Dr. Klein transitioned to Lilly’s Global Health Outcomes organization where over the next six years he held leadership roles associated with development across product and program phase research as well as the development of business management and operations capabilities including quality, capacity planning, capability management and development, strategic planning, and project management. In January of 2010, Dr. Klein returned to Lilly USA to assume responsibilities for strategic transformation efforts within the Outcomes Research organization and then in 2011, he took on responsibility for the Regional Outcomes Research teams globally. Dr. Klein assumed his current responsibilities in Oncology drug development in 2014.

Maria Koehler, M.D., Ph.D.,
Vice President
Oncology Strategy, Innovation, Collaborations
Pfizer Oncology

Maria Koehler, M.D., Ph.D., is the Vice President Oncology Strategy, Innovation and Collaborations for the Oncology Business Unit of Pfizer Inc. Dr. Koehler is responsible for creating and coordinating strategies for innovative approaches in patient’s engagement, novel endpoints and value generation, as well as the development of Pfizer portfolio compounds and for broad collaborations with academia and pharma.

Before joining Pfizer, Dr. Koehler served as the Executive Director and Group Leader of the Medicine Development Center of GlaxoSmithKline Oncology and as the Oncology Designated Member for Center of Excellence for External Drug Discovery and Business Development. She also served as Senior Medical Director for Research and Development, Emerging Products/Oncology at AstraZeneca. In Dr. Koehler’s previous academic appointments, she served as the Clinical Director of Bone Marrow Transplantation, Hematology/Oncology Department at University Hospital in Pittsburgh, PA and Director of the Bone Marrow Transplant Program and Associate Professor at the St. Christopher’s Hospital in Philadelphia, PA.

A board-certified hematology/oncology physician, Dr. Koehler received her M.D. and Ph.D. from the Silesian School of Medicine in Katowice, Poland. She is a scientific advisor to several biotech companies and author of more than 160 original publications and chapters in oncology.

Thomas Lynch, Jr., M.D.
Executive Vice President
Chief Scientific Officer, Research & Development
Bristol-Myers Squibb

Dr. Thomas Lynch joined Bristol-Myers Squibb in March 2017 as Executive Vice President and Chief Scientific Officer of Research & Development, bringing broad leadership experience, significant experience in drug development and a deep understanding of the patient perspective as a treating oncologist. He previously served as a Director on Bristol-Myer Squibb's Board from 2013 - 2017.

Tom has more than 30 years of medical, management and leadership experience, including more than 23 years at Massachusetts General Hospital (MGH). He served as Chairman and Chief Executive Officer of Massachusetts General Physicians Organization and as a member of the MGH Board from 2015 to 2017. Before his roles as Chairman and CEO at MGH, Tom served as the Director of Yale Cancer Center and was the Richard and Jonathan Sackler Professor of Internal Medicine at the Yale School of Medicine from 2009 to 2015. He also served as the Physician in Chief of Smilow Cancer Hospital, Yale New Haven from 2009 to 2015. Prior to 2009, he served as Professor of Medicine at Harvard Medical School and Chief of Hematology/Oncology at Massachusetts General Hospital. While at MGH in 2004, Tom was part of the team credited with the significant discovery that certain genetic mutations in lung cancer patients caused therapies to work for some individuals and not for others.

Tom is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer.

Howard McLeod, Pharm.D.
Medical Director
DeBartolo Family Personalized Medicine Institute
Moffitt Cancer Center

Dr. Howard McLeod is Medical Director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center. He is chair of the Department of Individualized Cancer Management and a State of Florida Endowed Chair in Cancer Research. He is also a Senior Member of the Division of Population Sciences and Professor at the University of South Florida.

Dr. McLeod is chair of the NHGRI eMERGE network external scientific panel and a recent member of the FDA committee on Clinical Pharmacology and the NIH NHGRI Advisory Council. Since 2002, Dr. McLeod has been vice chair for Pharmacogenomics for the NCI clinical trials group CALGB/ALLIANCE, overseeing the largest oncology pharmacogenomics portfolio in the world. Dr. McLeod is also a 1000 talent scholar of China and a Professor at Central South University in Changsha, China. Dr. McLeod is an active entrepreneur, serving on the Board of Directors, Scientific Advisory Board and as a domain expert consultant to publically traded and privately held companies. He has also founded both for-profit and non-profit companies in the USA and China. Howard has published more than 500 peer reviewed papers on pharmacogenomics, applied therapeutics or clinical pharmacology and continues to work to advance individualized medicine.

Lincoln Nadauld, M.D., Ph.D.
Executive Director, Precision Medicine, Precision Genomics
Intermountain Healthcare

Dr. Lincoln Nadauld is the Executive Director of Precision Medicine and Precision Genomics at Intermountain Healthcare. His team is extending the lives and improving quality of life for late-stage cancer patients locally, nationally and internationally. Dr. Nadauld helped to develop technologies at Stanford University that identify DNA changes in cancer to predict whether or not a targeted cancer drug might be effective for a specific patient.

Originally from Utah, Dr. Nadauld attended Brigham Young University for his undergraduate degree and went on to complete medical and doctoral degrees followed by an internship and residency at the University of Utah. He completed a clinical fellowship in medical oncology and Ph.D. at Stanford University where he continues to be involved in research collaborations. He was awarded the prestigious Young Investigator Award by the American Society of Clinical Oncology and the Career Development Award of the National Cancer Institute. His research has been featured in many publications, including the Journal of Oncology Practice, a publication of the American Society of Clinical Oncologists.

Joshua Ofman, M.D., M.S.H.S.
Senior Vice President, Global Value, Access
and Policy

Joshua Ofman is currently the Senior Vice President of Global Value, Access & Policy at Amgen. He received his advanced medical training in Gastroenterology from UCLA and his Health Services Research training from the RAND/UCLA/VA program. He formally was a member of the academic faculty in the Department of Medicine, UCLA School of Medicine, Cedars-Sinai Medical Center. Dr. Ofman also served as the Senior Vice President of Zynx Health Inc., a consulting company focused on evidence-based clinical information for quality improvement, and reimbursement and health economics strategy for life sciences companies.

Dr. Ofman currently represents Amgen on the Boards of Directors of California Life Sciences Association (CLSA), Biotechnology Innovation Organization (BIO), and Chairman of the Boards of Directors for the National Pharmaceutical Council for 2017 (NPC).

Bryce Olson
Global Marketing Director, Health and Life Sciences Group
Intel Corporation

Bryce Olson is the Global Marketing Director for Intel’s Health and Life Sciences group. One of the areas he focuses on is bringing technology and science together in the exciting area of genomics and precision medicine with a powerful message on how this saves lives. Genomic sequencing and precision medicine gave him a life he didn’t think he’d get to live.

Bryce is inspired by connecting the advances in life sciences into clinical settings and helping patients understand these new opportunities. He is a sought after keynote speaker both locally and nationally, and his story has been covered by both local and national media. Bryce also started FACTS (‘Fighting Advanced Cancer Through Songs’), a movement that uses the power of music to build awareness for a new way to fight cancer and bring molecular testing and precision medicine to other advanced cancer patients. In 2017, Bryce wrote and co-produced a rock-n-roll album with proceeds going towards the FACTS movement, that brought together a variety of Portland, Oregon based musicians and singers including Jenny Conlee from the Decemberists, Martha Davis from the Motels, Pete Krebs, and Michelle DeCourcy – all four of whom are also cancer survivors.

Ronald A. Paulus, M.D., M.B.A.
President, CEO
Mission Health

Ronald A. Paulus, M.D., M.B.A., is President and CEO of Mission Health, a $1.7 billion integrated health system serving all of western North Carolina – a region older, poorer, sicker and less likely to be insured than state and national averages. During his tenure, Mission Health has reduced inpatient mortality by more than half, achieved six-sigma medication safety results, improved patient experience to above the 90th percentile and became the only health system ever designated as one of the nation’s Top 15 Health Systems for four consecutive years and five of six years (Thomson Reuters in 2012, and its successor Truven Health Analytics/IBM Watson in 2013-2015 and 2017).

Before joining Mission Health, Dr. Paulus served as Executive Vice President, Clinical Operations and Chief Innovation Officer for Geisinger Health System as well as co-founder, President and later CEO of CareScience, Inc., later acquired by Premier, Inc.

Dr. Paulus has been named one of Modern Healthcare’s Top 50 Most Influential Physician Executives and Leaders several times, and was recently among the Top 15 on that list. Dr. Paulus received his M.D. degree from The School of Medicine, University of Pennsylvania, and his M.B.A., concentration in healthcare management, and B.S. in Economics from The Wharton School, University of Pennsylvania.

Steven D. Pearson, M.D., M.Sc.
Institute for Clinical and Economic Review

Steven D. Pearson is the Founder and President of the Institute for Clinical and Economic Review (ICER), an independent non-profit organization that evaluates the evidence on the value of medical tests, treatments and delivery system innovations to encourage collaborative efforts to improve patient care and control costs. Prominent among its evidence reports are ICER reviews of new drugs that include full assessments of clinical and cost-effectiveness along with suggested “value-based price benchmarks” to inform policymakers and guide price and coverage negotiation.

Dr. Pearson is a Lecturer in the Department of Population Medicine at Harvard Medical School and also serves as Visiting Scientist in the Department of Bioethics at the National Institutes of Health. He received his medical degree from UCSF and completed an internal medicine residency and research fellowship at Brigham and Women’s Hospital. From 2005 - 2006, he served during the Bush administration as Special Advisor on Technology and Coverage Policy within the Coverage and Analysis Group at the Centers for Medicare and Medicaid Services. Dr. Pearson has also been a Senior Visiting Fellow at England’s National Institute for Health and Care Excellence (NICE), a Board Director of HTAi, the international society of health technology assessment agencies, and the Vice Chair of the Medicare Evidence Development and Coverage Advisory Committee (MedCAC).

Kristin Pothier
Global Head of Life Sciences

Kristin Ciriello Pothier is the Global Head of Life Sciences for the Parthenon-EY practice of Ernst & Young LLP and the creator of EY Precision Medicine™. She has more than 20 years of experience in management consulting and research in the life sciences industry. She is a noted speaker, workshop leader and writer in life sciences. She is also a clinical laboratory and life sciences innovation expert, helping develop product and service strategies worldwide for investors, corporations, and medical institutions. Her book, Personalizing Precision Medicine: A Global Voyage From Vision To Reality, was released in August of 2017. Earlier in her career, Kristin was a partner and owner of Health Advances, a healthcare consulting firm, and a research scientist at Genome Therapeutics and at Genzyme. She earned a B.A. in Biochemistry from Smith College and an M.S. in Epidemiology, Health Management, and Maternal and Child Health from the Harvard School of Public Health.

Scott D. Ramsey, M.D., Ph.D.
Hutchinson Institute for Cancer Outcomes Research

Dr. Scott D. Ramsey is a general internist and health economist. He is a Full Member in the Cancer Prevention Program, Public Health Sciences Division at the Fred Hutchinson Cancer Research Center, where he directs Hutchinson Institute for Cancer Outcomes Research, a multidisciplinary team devoted to clinical and economic evaluations of new and existing cancer prevention, screening and treatment technologies. In addition, Dr. Ramsey is a Professor in the Schools of Medicine and Pharmacy at the University of Washington.

Trained in medicine and economics, Dr. Ramsey’s research focuses on economic evaluations in cancer. He has published widely on patterns of care, costs and cost-effectiveness of treatments for lung, colorectal and prostate cancer. His research portfolio and interests include: large scale SEER-Medicare/Cancer Registry data linkages, patient reported outcomes, economic modeling of health care interventions, cost-effectiveness analysis, quality of life assessment, patterns of care, health care utilization, economic burden of disease for patients and society, pragmatic trial design, early technology assessment, and stakeholder engagement.

Dr. Ramsey is Co-Chair of the Outcomes and Comparative Effectiveness Committee of the Southwest Oncology Group, past President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and has served on the IOM Cancer Policy Forum.

Hakan Sakul, Ph.D.
Vice President, Head of Diagnostics, Genome Sciences
& Technologies, Worldwide R & D

Hakan Sakul leads Pfizer’s Companion Diagnostics (CDx) efforts across the enterprise. Dr. Sakul worked in the biotech industry in human genetics and statistical genetics before moving to Parke-Davis Pharmaceuticals. Following the merger of Parke-Davis with Pfizer, he held positions of increasing responsibility, including Director/Site Head for Clinical Pharmacogenomics, Sr. Director of Molecular Profiling, and Sr. Director of Translational Oncology. Dr. Sakul worked with Pfizer’s Executive Leadership Team and Board of Directors to define and implement Pfizer’s CDx strategy. One of his most significant professional accomplishments was to lead the CDx program for Xalkori®, Pfizer’s flagship program in companion diagnostics, to FDA approval simultaneously with the drug in August 2011.

He is a member of the Board of the Personalized Medicine Coalition, and author of over 30 referred scientific articles as well as many other papers, abstracts and book chapters. Hakan is keenly interested in technologies to identify patient sub-groups for targeted treatments and development of CDx to advance Precision Medicine.  His formal education includes B.S. and M.S. degrees from Ankara University in Turkey, Ph.D. in Quantitative Genetics from the University of Minnesota as a Rotary Foundation Scholar, and postdoctoral studies at University of California-Davis.

Michael S. Sherman, M.D., M.B.A.
Chief Medical Officer
Senior Vice President
Harvard Pilgrim Health Care

Dr. Michael Sherman serves as Chief Medical Officer and Senior Vice President for Harvard Pilgrim Health Care. Dr. Sherman has been a leader in driving adoption of outcomes-based provider and pharmaceutical contracts, and is responsible for Harvard Pilgrim’s medical trend management, provider engagement strategy, medical informatics, wellness and health promotion initiatives, care and disease management services, pharmacy services, NCQA accreditation and quality and utilization management programs. He serves on the faculty of Harvard Medical School’s Department of Population Medicine, as chair of the board of managers of the Harvard Pilgrim Health Care Institute, on the advisory board of the Institute for Clinical and Economic Review (ICER), and on the board of directors for the Personalized Medicine Coalition. Dr. Sherman also is the current chair for AHIP’s CMO Leadership Council, comprising chief medical officers from health plans throughout the United States.

Prior to joining Harvard Pilgrim, Dr. Sherman held leadership roles at Humana, UnitedHealth Group, and Thomson Medstat (now IBM Truven). He holds a B.A. and an M.S. in biomedical anthropology from the University of Pennsylvania and received his M.D. from Yale and M.B.A. from the Harvard Business School.

Jennifer Snow, M.P.H.
Director, Health Policy

Jennifer Snow, M.P.H., is a Director of Health Policy at Xcenda and keeps clients and stakeholders informed on the latest legislative and regulatory updates and their commercial impact. Her team analyzes the health care environment and provides strategic guidance on how to best navigate challenges to coverage and access. Ms. Snow is a subject matter expert on the Affordable Care Act, quality measures, medication adherence and federal health programs, particularly the Medicare Prescription Drug Benefit (Part D). She has experience with reimbursement and policy strategy launch plans for various therapeutic areas including cardiovascular, respiratory, mental health, diabetes, oncology and rheumatoid arthritis.

Before joining Xcenda, Ms. Snow was a Director of Policy at a large pharmaceutical manufacturer. Ms. Snow also worked at the Centers for Medicare & Medicaid Services in the Office of Exchanges, where she developed and formulated policies on essential health benefits, oversight, essential community providers and basic health plans. She also has expertise in healthcare coverage and access issues from her time with Avalere as well as her experience at Stanford University as a Senior Benefits Analyst.

Ms. Snow holds an M.P.H. from the University of North Carolina-Chapel Hill and a B.S. in Russian from Georgetown University.

Meg Tirrell, M.S.J.

Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC's Business Day programming, contributes to and is based at the network's global headquarters in Englewood Cliffs, N.J.

Tirrell has covered development of new drugs for Alzheimer's, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika. Her work has explored why fewer drugs are developed for children, chronicled the sequencing of her own genome, and followed the manufacturing of a flu shot from egg to pharmacy. In 2014, she revealed the agonizing decision-making behind Compassionate Use of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on development of new medicines.

Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek. She holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College.